

ACCELERATING CARE: FARICIMAB VS AFLIBERCEPT FOR DISCHARGE/READMISSION IN NAMD



Jaskaran Singh Bhangu, Chris Stewart, Rhadika Rewal, Keioni Essex, Ahmad Sam Fattouh, Safa Elhassan, Gwyn Williams
Ophthalmology department, Singleton Hospital, Swansea Bay University Health Board, Swansea, Wales, UK.




Introduction

nAMD is the primary cause of central vision loss. Efficient service delivery—discharging to community and reducing readmission—is a key challenge for NHS ophthalmology.

Method

Retrospective audit (Nov 2022 – Dec 2025) of 1,004 eyes. Comparisons between Faricimab and Aflibercept stratified by lesion morphology (Types 1, 2, Pre-papillary).



Service Level Outcomes




Time to Discharge:



Readmission Analysis

Readmission was significantly lower for Faricimab:



Conclusion: Faricimab facilitates faster discharge and significantly lower readmission. Extended dosing helps manage capacity.

